https://www.selleckchem.com/pr....oducts/tideglusib.ht
When EQD2 is 70Gy, the number of CD8-positive cells has a significant impact on treatment outcome the recurrence rate (local recurrence rate + distant metastasis rate) was 46.2% in the group with a CD8 value of 230 or higher, whereas the recurrence rate was 75.7% in the group with a CD8 value of less than 230. The combination of CD8 or FoxP3 with EQD2 can be potentially useful to predict the treatment results of radiotherapy for cervical cancer, leading to individualized optimal selection of treatment for cervical cancer. The com